University of Technology, Sydney
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of Technology, Sydney
In Q4 2014 start-ups raised $1.5 billion, a new record. Several companies penned alliances with tech transfer entities; eight start-ups were acquired.
Defymed Inc.’s MAILPAN (MAcro-encapsulation of PANcreatic Islets) is a bioartificial pancreas that can use a broader pool of cell types while protecting the cells from rejection by the immune system.
Derived from Strategic Transactions, a premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly review of licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Device, and Pharmaceutical sectors. This month’s column covers deals announced September through October 2014.
- Academic and Research Institutions
- Other Names / Subsidiaries
- New South Wales Institute of Technology
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.